Analysts expect that Minerva Neurosciences Inc (NASDAQ:NERV) will report earnings of ($0.33) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences posted earnings per share of ($0.24) in the same quarter last year, which suggests a negative year over year growth rate of 37.5%. The firm is scheduled to report its next earnings results on Monday, March 11th.
On average, analysts expect that Minerva Neurosciences will report full year earnings of ($1.28) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($1.48) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Minerva Neurosciences.
Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.07.
Several research firms recently commented on NERV. BidaskClub upgraded Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 26th. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Friday, November 9th. Finally, ValuEngine upgraded Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 23rd.
Shares of Minerva Neurosciences stock opened at $7.91 on Friday. The stock has a market cap of $303.59 million, a PE ratio of -7.32 and a beta of 1.57. Minerva Neurosciences has a twelve month low of $5.00 and a twelve month high of $12.95.
In related news, Director William F. Doyle purchased 4,000 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was bought at an average price of $9.88 per share, for a total transaction of $39,520.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $39,520. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Venture Associates L. Index III sold 15,444 shares of Minerva Neurosciences stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $12.35, for a total value of $190,733.40. The disclosure for this sale can be found here. In the last quarter, insiders purchased 10,600 shares of company stock valued at $103,920 and sold 106,717 shares valued at $1,326,610. Company insiders own 9.60% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC bought a new stake in Minerva Neurosciences in the second quarter worth about $135,000. Falcon Point Capital LLC lifted its stake in Minerva Neurosciences by 28.6% in the third quarter. Falcon Point Capital LLC now owns 27,933 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 6,209 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Minerva Neurosciences by 329.4% in the second quarter. Acadian Asset Management LLC now owns 32,060 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 24,594 shares during the last quarter. Alpine Woods Capital Investors LLC lifted its stake in Minerva Neurosciences by 150.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $413,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in Minerva Neurosciences by 38.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 65,567 shares of the biopharmaceutical company’s stock worth $541,000 after purchasing an additional 18,267 shares during the last quarter. Institutional investors own 75.09% of the company’s stock.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Read More: Diversification
Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.